Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

Century Therapeutics LLC appointed Joseph Jimenez, former CEO of Novartis AG (NYSE:NVS; SIX:NOVN), to its board. Jimenez retired in 2018 after eight years at the pharma’s helm, leading it through multiple patent expirations, business integrations and reorganizations (see “CMO Narasimhan to Replace CEO Jimenez”).

Century, which is using iPS cells to develop allogeneic cell therapies, also hired Greg Russotti as chief technology officer. He was VP of cell therapy technical development at Celgene Corp. (see “Versant, Bayer Bet Big on iPS Cells”)...